           Identification FKS1 Gene Candida albicans              Essential Target 1,3-b-D-Glucan Synthase Inhibitors

             Pneumocandins echinocandins fungicidal antibiotics, currently clinical development, inhibit
          1,3-b-D-glucan synthase (GS) human fungal pathogens. identified gene diploid
          organism Candida albicans encodes target inhibitors. 2.1-kb portion gene, designated
          CaFKS1, significant homology Saccharomyces cerevisiae FKS1 FKS2 genes, encode partially
          functionally redundant subunits GS. evaluate role CaFks1p susceptibility echinocandins,           disrupted CaFKS1 homolog spontaneous pneumocandin-resistant C. albicans mutants
          CAI4R1, NR2, NR3, NR4. mutants selected previously agar plates containing           pneumocandin L-733,560. clones derived transformation resistant (Echr) fully
          sensitive (Echs) inhibition L-733,560 liquid broth microdilution vitro GS assays. site
          plasmid insertion transformants mapped Southern blot analysis, using restriction site
          polymorphisms CaFKS1 gene distinguish alleles (designated CaFKS1h CaFKS1b).
          strains CAI4R1 NR2, CaFKS1b allele disrupted Echr transformant; strain NR4,
          CaFKS1h disrupted Echr transformant. conclude   strains CAI4R1, NR2, NR4           heterozygous dominant semidominant pneumocandin resistance mutation CaFKS1, (ii) drug
          resistance mutations occur CaFKS1 allele, (iii) CaFks1p target echinocandins.           transformants strain NR3, clones analyzed uniformly Echr, CaFKS1h allele,
          disrupted wild-type form, detected genomic Southern blots. believe gene conversion           CaFKS1 locus produced Cafks1h alleles contain Echr mutation. Transformants
          derived mutants analyzed susceptibility pneumocandin treatment mouse model           disseminated candidiasis. Strains heterozygous resistant allele  e., C. albicans CAI4R1, NR2, NR4)
          moderately resistant treatment, strains functional Echs allele  e., strain NR3           derivatives strain CAI4R1 disruption plasmid integrated Echs allele) displayed strong vivo
          echinocandin resistance. Finally, unable inactivate alleles CaFKS1 step integrative
          disruption, suggesting CaFks1p likely essential protein C. albicans.


   Semisynthetic derivatives pneumocandin B0 (MK0991;                     following model emerged. S. cerevisiae genes, FKS1 L-743,872) echinocandin B (LY303366) li-                    FKS2, encode highly homologous, large integral
popeptide antifungals currently clinical trials          membrane proteins function catalytic subunit GS
treatment systemic fungal infections (5, 33). com-                  (11, 22, 37). small GTP-binding subunit, Rho1p, pounds inhibit synthesis 1,3-b-D-glucan,                  necessary activity (13, 20, 24, 36, 41). FKS1 expression essential polysaccharide walls   fungal            cell cycle regulated abundant vegetative
pathogens (3, 10, 18). broader-spectrum semisynthetic                    growth, FKS2 expression calcineurin dependent derivatives increased potency vitro animal mod-               important efficient sporulation (37). Mutations conferring
els fungal infection, improved potency function              high-level resistance lipopeptides  Echr phenotype) map increased activity 1,3-b-D-glucan synthase (GS) (3,               FKS1 FKS2, GS complexes containing 30). Despite widespread enzyme target                Fks1p Fks2p sensitive inhibition lipopeptides (11,
tifungal therapy, questions remain components                 37). mutant alleles confer resistance GS inhibitors, synthetic complex, mechanism echinocandin                   cells assays GS activity, resistance
hibition, potential resistance fungal patho-              phenotype semidominant diploids. role Fks1p gens.                                                                        glucan synthesis supported Inoue et al. (22),
   susceptibility Saccharomyces cerevisiae GS inhibi-              identified gene products FKS1 FKS2 enzyme
tors used identify characterize genes play              preparations enriched GS activity. expected role 1,3-b-D-glucan synthesis (9, 11, 12, 15). Based                 essential cellular function, mutants survive studies resistant mutants (9, 11, 12, 15), gene disruption                FKS1 FKS2 disruption genes experiments (11, 22, 37), biochemical characterization,              lethal (22, 37).
                                                                                using portion S. cerevisiae FKS1 probe, genes
                                                                             strong homology identified fungal patho-
   * Corresponding author. Mailing address: Department Biochem-
istry, Merck Research Laboratories RY80Y-220, P.O. Box 2000, Rah-            gens Candida albicans, Aspergillus fumigatus, Cryptococcus
way, NJ 07065-0900. Phone: (732) 594-5124. Fax: (732) 594-1399. E-           neoformans (11). homolog fksA recently cloned
mail: Myra_Kurtz@Merck.com.                                                  Aspergillus nidulans (25). deduced amino acid se-
   † Present address: Chrysalis Corporation, Princeton, NJ 08544.            quence FksAp significantly conserved S. cerevi-

                                                                      2471
 2472       DOUGLAS ET AL.                                                                                                    ANTIMICROB. AGENTS CHEMOTHER.


siae Fks proteins, particularly central domain                            DNA transformed C. albicans spheroplast method (29)
predicted hydrophilic cytoplasmic face                       lithium acetate method (14). Transformants selected SC Ura2 medium
                                                                                     purified tested growth YPDA agar plates containing L-733,560
protein. explore role FksAp glucan synthesis, Kelly                     0.5 mg/ml.
et al. (25) raised antisera synthetic peptides designed                         DNA sequence analysis performed manufacturer’s directions, FksAp sequence demonstrated cross                             using Sequenase v. 2.0 (U.S. Biochemicals), [32P]dCTP (Amersham) oligo-
acting protein expected molecular weight                             nucleotide primers synthesized Merck purchased New England Bio-
                                                                                     labs Gibco BRL. Software Mac Vector (Oxford Molecular Group) tected strongly enriched partial purification GS                       Genetics Group used analyze DNA sequences.  nidulans. enzyme activity susceptible li-                           Northern blotting performed according manufacturer’s directions,
popeptide inhibition, hyphae Aspergillus spp.                          using mRNA prepared polyATract (Promega). Samples come distended highly branched, vitro (32)                        separated 1  agarose gel containing formaldehyde, transferred nylon
                                                                                     membrane (Amersham), probed DNA fragment radiolabeled vivo (28), exposed GS inhibitors. results support                        [32P]dCTP random priming. idea FksAp component GS complex                            Plasmid constructions. Total genomic DNA C. albicans CAI4 di-  nidulans target echinocandins.                                       gested KpnI BamHI, fragments separated 0.6  agarose
   recent vitro selection spontaneous L-733,560-resis-                      gel. DNA lane probed fragments homologous 1.3-kb
                                                                                     ClaI-SalI probe S. cerevisiae FKS1 gene (11). used signal tant mutants C. albicans Ura2 strain CAI4 yielded rare                        Southern blot guide excise KpnI-BamHI fragments appropriate
isolates phenotypes similar S. cerevisiae                     size gel clone YEplac195 (17). E. coli clones transformed
lipopeptide-resistant mutants (27). cell resistance                        minilibrary pooled probed mWave colony hybridiza- mutant (strain CAI4R1) reflects resistance                         tion kit (Invitrogen). Plasmid DNA isolated putative clones,                                                                                      insert identified Southern blotting. 2.1-kb KpnI-BamHI fragment
zyme activity, results spheroplast fusion experiments                       clones (pGJ1) isolated subcloned pUC19 (New consistent semidominant mutation single gene                         England Biolabs) yield pJAD1.
(27). S. cerevisiae mutants, resistance pheno-                          Plasmid pJAD1DXH derived plasmid pJAD1 ligating filled type specific GS inhibitors. understand nature                       XbaI HindIII sites yield vector unique SalI site insert
                                                                                     DNA. pJAD1DXH digested BamHI phosphatase ligated echinocandin resistance spontaneous mutants,                         URA3 gene carried 2.9-kb BamHI fragment plasmid pMB-7 (16) explore role C. albicans homolog FKS1 sus-                          create plasmids pAM600 pAM601, differ orientation ceptibility GS inhibitors, cloned sequenced portion                      URA3 fragment. disruption plasmid pAM602 created removing homologous gene (CaFKS1) used integrative                          0.6-kb SalI-BclI fragment plasmid pJAD1DXH replacing                                                                                      3.9-kb SalI-BglII fragment plasmid pMB-7, carries hisG-URA3-
disruption C. albicans Echr mutants. results                          hisG cassette.
indicate mutations CaFKS1 allele confer                           Plasmid pJAM15 (35), C. albicans URA3 gene inserted vector
vitro resistance L-733,560, identifies CaFks1p                         pBR322, used transform strains CAI4, CAI4R1, NR2, NR3, NR4 target echinocandins C. albicans. transfor-                     uridine prototrophy.
                                                                                        GS assays. measured vitro synthesis 1,3-b-D-glucan UDP-
mants retained ability produce lethal infection mice,                    [3H]glucose, using crude membranes prepared described previously (12). disruption Echs allele correlated significant                        assay measures formation radiolabeled trichloroacetic acid (TCA)-insol-
resistance treatment infected animals L-733,560.                      uble material. Briefly, cells logarithmic phase harvested centrifuga-
absence DNA highly homologous CaFKS1 Southern                               tion, washed, broken glass beads. Debris unbroken cells                                                                                      removed centrifugation 4,000 3 g, crude membranes harvested
blots C. albicans total genomic DNA, inabil-                       supernatant fraction centrifugation 100,000 3 g. resulting
ity recover null mutations CaFKS1 alleles, suggests                       pellet resuspended 1/50 original culture volume stored aliquots functional redundancy gene C.                       280°C. GS assay, reaction mixtures incubated microtiter dishes albicans. clinical implications results dis-                        gentle agitation 2 h quenched equal volume ice-cold 20 
                                                                                     TCA. Precipitated product harvested glass-fiber filter mats (Pharmacia)
cussed.                                                                              washed water 96-channel cell harvester (Cambridge Technology).
                                                                                     mats dried, sealed bags scintillation cocktail, counted                         MATERIALS METHODS
                                                                                     Betaplate scintillation counter (LKB/Wallac). counting efficiency    Strains, media, antibiotics, growth conditions. C. albicans CAI4 (16)     estimated 40 . gift W. Fonzi (Georgetown University). Echr mutants CAI4R1, NR2,             vivo analysis. Uridine prototrophic derivatives wild-type mutant
NR3, NR4 described previously (27). semisynthetic pneu-            strains tested described previously (27) virulence mice. 50 
mocandin L-733,560 (6) synthesized Merck (Rahway, N.J.) shown         lethal doses (LD50s) calculated Knudsen-Curtis method (26). Strains .95  pure high-performance liquid chromatography. Amphotericin B,           tested susceptibility L-733,560 amphotericin B treatment itraconazole, ketoconazole, nystatin, 5-fluorocytosine obtained        disseminated candidiasis target-organ assay described previously (4). 99 
Sigma. Fluconazole Merck chemical collection. Strains grown        effective dose (ED99) determined based reduction number 30°C yeast extract-peptone medium adenine, uridine        CFU/gram kidney compared sham-treated control mice described pre-
supplementation (YPDA YPDAUd, respectively), defined medium              viously (2). mice used group experiment. procedures (SC Ura2) described previously (27). Values MIC 50  inhibi-        performed accordance highest standards humane handling,
tion growth L-733,560 determined liquid broth microdilution          care, treatment research animals approved Merck Insti-
assay YPDA, YPDAUd, Yeast Nitrogen Base (Difco) 2                  tutional Animal Care Use Committee. care use research animals
glucose. Briefly, cells grown mid-logarithmic phase subcultured        Merck meet exceed applicable local, national, international laws initial optical density 600 nm (A600) 0.01 seeded wells microtiter   regulations.
dishes contained serial twofold dilutions L-733,560. Growth inhibition          Nucleotide sequence accession number. nucleotide sequence determined 24 h 30°C eye  MICs) measuring A600         2,069-bp KpnI-BamHI fragment CaFKS1 assigned GenBank acces- spectrophotometer (Tecan) comparing results control      sion  AF027295. containing drug.
   DNA RNA methods. DNA manipulations performed described Maniatis et al. (34). Wizard Preps (Promega) kits Qiagen, ,                                       RESULTS
used isolate plasmids, DNA fragments purified Gene Clean
Kit (Bio101). Enzymes digestion, ligation, dephosphorylation DNA             C. albicans homolog S. cerevisiae FKS1. Fks proteins Gibco BRL. Competent cells Escherichia coli DH5a used transformations.
                                                                                     S. cerevisiae (Fks1p Fks2p)  nidulans (FksAp)
   Total genomic DNA isolated C. albicans strains method          large integral membrane proteins share highly ho-
Holm et al. (21). Southern blot analysis, probes prepared random priming      mologous internal domain (domain  predicted (Stratagene) [32P]dCTP (Amersham) hybridized DNA               cytoplasmic plasma membrane. Regions digested restriction enzymes transferred Zeta Probe GT mem-
branes (Bio-Rad) PosiBlot pressure blotter (Stratagene) according                                                                                      domain homology BcsAp, catalytic subunit
manufacturer’s directions. Blots washed conditions high stringency     Acetobacter xylinium cellulose synthase (25). used analyzed autoradiography.                                                     1.3-kb ClaI-SalI DNA fragment FKS1, encodes  VOL. 41, 1997                                                                                                         FKS1 GENE C. ALBICANS                    2473




   FIG. 1. Alignment CaFks1p predicted Fks protein sequences S. cerevisiae FKS1 (U12893), S. cerevisiae FKS2 (U16783),  nidulans fksA (U51272).
GenBank accession numbers given parentheses. 2,069-bp KpnI-BamHI CaFKS1 fragment C. albicans CAI4 analyzed using software Genetics Group. 689-amino-acid uninterrupted reading frame identified aligned Fksp sequences using clustal program. Domain S. cerevisiae Fks1p begins position 261 figure extends position 688. Conserved residues boxed, gaps indicated dashes. regions shown alignment follows: S. cerevisiae Fks1p, residues 460 1147; S. cerevisiae Fks2p, residues 479 1166;  nidulans Fks1p, residues 492 1178.




portion large cytoplasmic domain, clone KpnI-                              CaFKS1 alleles HindIII site 59
BamHI fragment homologous gene C. albicans                             region (Fig. 2B). used restriction fragment length
create plasmid pJAD1. expected, protein sequence                             polymorphism distinguish alleles subsequent experi- uninterrupted reading frame predicted fragment                           ments. purposes, 6.7-kb HindIII-HindIII fragment
shows strong homology Fks1p, Fks2p, FksAp, particu-                             produced digestion genomic DNA strain CAI4 larly domain (Fig. 1). Northern blot poly  RNA                         HindIII PvuII defines CaFKS1h allele, 8.5-kb C. albicans CAI4 probed KpnI-BamHI frag-                             PvuII-HindIII fragment defines CaFKS1b allele.
ment pJAD1, single transcript ca. 7 kb                                  Integrative transformation CaFKS1 locus Echr
detected (data shown). chosen FKS1                             mutants. Strain CAI4R1 spontaneous Echr mutant derived open reading frame contains KpnI-BamHI                               strain CAI4 described previously (27). used fragment, given significant degree homology members                          cloned fragment CaFKS1 characterize mutation FKS gene family convention using                            CAI4R1. Plasmid pAM600 (Fig. 2C), contains C.
nomenclature C. albicans S. cerevisiae genes. refer                         albicans URA3 gene, internal fragment CaFKS1, CaFKS1 avoid confusion S. cerevisiae                         pUC19 backbone, linearized CaFKS1 insert gene.                                                                                  digestion SalI transformed CAI4R1. Integration
   used CaFKS1 fragment pJAD1 map gene                             Cafks1-1 locus expected disrupt strain CAI4 Southern blotting. region                               alleles according scheme outlined Fig. 2D E. KpnI BamHI sites plasmid clone genome                               Ura1 transformants characterized Echr, colinear. Digestion genomic DNA strain CAI4                               Echs. mapped site inte- enzymes sites                          gration Echr isolates (T25 T26) Echs
KpnI-BamHI fragment pJAD1 produced single cross-                             isolates (T28 T32) Southern blotting. Fig. 2A, hybridizing band autoradiograms; additional fragments                            alleles CaFKS1 locus strains CAI4 CAI4R1 weak homology probe visible (data                                 transformants distinguished digestion shown).  digestion genomic DNA HindIII                             PvuII HindIII. transformants T25 T26, PvuII generated distinct fragments Southern blots (Fig.                         6.7-kb HindIII-HindIII fragment intact 8.5-kb
2A, lane 1), despite fact sites                       PvuII-HindIII fragment replaced novel fragments enzymes KpnI-BamHI CaFKS1 fragment pJAD1.                                7.9 6.1 kb. Transformants T28 T32 retained 8.5-kb fragment pattern consistent polymorphism                                PvuII-HindIII fragment, 6.7-kb HindIII-HindIII frag-
 2474       DOUGLAS ET AL.                                                                                                  ANTIMICROB. AGENTS CHEMOTHER.


                                                                                     values T28 T32. shown previously                                                                                      inhibition curve CAI4R1 unlike titration curves
                                                                                     described S. cerevisiae Echr mutants C. albicans
                                                                                     Echr mutant strain CA-2 (27). IC50 L-733,560                                                                                      enzyme strain CAI4R1 increased fourfold rela-
                                                                                     tive strain CAI4, inhibition did exceed
                                                                                     55 , highest concentrations drug tested (27).
                                                                                        used disruption pAM600 characterize Cafks1
                                                                                     alleles additional spontaneous L-733,560-resistant mu-
                                                                                     tants derived C. albicans CAI4: strains NR2, NR3,                                                                                      NR4 (27) (Table 1). C. albicans NR2 NR4, like strain
                                                                                     CAI4R1, yielded Echr Echs isolates trans-
                                                                                     formed pAM600. Strain NR2 equivalent CAI4R1
                                                                                     CaFKS1b allele disrupted Echr Ura1
                                                                                     transformants, Cafks1h allele disrupted Echs
                                                                                     Ura1 transformants (data shown). contrast, strain
                                                                                     NR4 transformed pAM600, loss resistance




    FIG. 2. Integration plasmid pAM600 CaFKS1 locus C. albicans
CAI4R1.   Southern blot pAM600 transformants. Genomic DNAs wild-type strain (CAI4 [lane 1]), original Echr mutant strain (CAI4R1 [lane
2]), Echr transformants (T25 [lane 3] T26 [lane 4]), Echs
transformants (T28 [lane 5] T32 [lane 6]) digested PvuII HindIII probed 2.1-kb KpnI-BamHI CaFKS1 fragment pJAD1. portion autoradiogram shown; arrows indicate migration
positions plasmid pAM602 digested KpnI (8.2 kb) plasmid
pJAD1DXH digested BamHI (4.7 kb). (B) Schematic maps CaFKS1h CaFKS1b alleles. Abbreviations restriction enzyme cleavage sites follows: P, PvuII; H, HindIII; K, KpnI; S, SalI; B, BamHI. K, S, B
sites included reference considered unique regions shown. Restriction fragments detected following digestion PvuII HindIII (circled) probing KpnI-BamHI CaFKS1 fragment illustrated dashed lines. stippled boxes depict regions homologous probe. (C) Map plasmid pAM600. pUC19 vector sequences (      ■    ), 2.9-kb BamHI fragment (■) containing C. albicans URA3 gene, 2.1-kb CaFKS1 KpnI-BamHI fragment (o) shown. Arrows circle illustrate directions transcription URA3, CaFKS1, E. coli
bla genes. plasmid linearized digestion SalI  line inter-
secting circle) prior transformation. (D E) Chromosomal maps fol-
lowing pAM600 integration CaFKS1. maps depict pAM600 integration CaFKS1b allele (D) CaFKS1h allele (E).




ment replaced novel fragments 6.1 5.8 kb. fragment sizes consistent integration pAM600, internal PvuII sites, CaFKS1b
allele T25 T26 Cafks1h-1 allele T28 T32
(Fig. 2D E).
   test phenotypes Cafks1::URA3/CaFKS1 transfor-
mants T25, T26, T28, T32, performed liquid broth                               FIG. 3. Susceptibilities CAI4R1 transformants pneumocandin L-733,560.
microdilution assay vitro GS assay (Fig. 3). Esti-                           Strains T25 (E), T26 (F), T28 (‚), T32 (Œ), CAI4 (h), CAI4R1 (■)
mated values 50  inhibition growth L-733,560 (Fig.                         grown YPDA assayed described Materials Methods. 3A) roughly 1,000-fold higher transformants T25                         drug prepared 10-mg/ml stock, final concentration ranged
                                                                                     6.1 3 1022 8.0 3 103 ng/ml. (B) Membranes prepared T26 (ca. 3,000 ng/ml) strains T28 T32 (ca. 0.2                       mid-logarithmic-phase cells glucan synthase activity measured 
0.8 ng/ml). original heterozygous mutant (CAI4R1)                            scribed Materials Methods. reaction mixtures contained 0.3 mg resistant, albeit slightly lesser extent. Figure 3B shows                  crude membrane protein ml 0.6 mM UDP-glucose UDP-[3H]glu- curves L-733,560 inhibition GS crude membrane                          cose added 25,000 dpm/nmol; final concentrations L-733,560                                                                                      5.1 3 1022 1.0 3 105 nM. 2 h 22°C, TCA-insoluble product preparations strain. like results                      harvested radioactive counts performed. specific activity cells, concentrations L-733,560 inhibit GS activity                   enzyme given Table 3. symbols panel B used
50  (IC50s) strains T25 T26 ca. 1,000-fold higher                       panel  error bars standard deviations.
 VOL. 41, 1997                                                                                                   FKS1 GENE C. ALBICANS                    2475


 TABLE 1. Susceptibilities CAI4R1 pAM600 transformants
      spontaneous Echr mutants NR2, NR3, NR4
                 Susceptibility                                 L-733,560             transformants       Disrupted allele
 Strain                                                           Echr
                                     MIC           IC50                             transformants
                                         Echr       EchS
               (mg/ml)       (nM)

CAI4R1            2          1,000         5          3          CaFKS1b
NR2               4         40,000         5          3          CaFKS1b
NR3             .16         30,000        75          0
NR4               8             40         6          2          CaFKS1h
     MIC determined YPDA medium measured outlined Materials Methods.




phenotype Ura1 transformants correlated disruption Cafks1b allele (data shown). data
suggest strains NR2 NR4, like mutant CAI4R1, heterozygous semidominant mutation conferring Echr                         FIG. 5. Inhibition L-733,560 GS activity mutant strains NR2 (F),
phenotype allele (Cafks1h) contains mutation                     NR3 (■), NR4 (Œ). Reactions performed described legend strains NR2 CAI4R1 allele (Cafks1b)                        Fig. 3B, membrane protein concentration ranged 0.4 0.8
                                                                                  mg/ml, incubation 30°C, UDP-[3H]glucose 7,500 dpm/nmol, contains mutation strain NR4. strain NR3, Echs                     L-733,560 titrated 5.5 3 1021 4.3 3 104 nM. Results clones recovered 75 Ura1 pAM600 transfor-                              wild-type strain (CAI4 [h]) shown. specific activity enzyme
mants; e., isolates grew SC Ura2 plates containing                   given Table 3.
0.5 mg L-733,560 ml. CaFKS1 locus NR3(pAM600) clones original NR3 mutant eval-
uated Southern blotting, results shown Fig.
                                                                                  pneumocandin resistant, increases IC50s rang-
4A. Restriction fragments 5.8, 6.1, 6.7 kb detected
                                                                                  ing 20-fold (NR4) roughly 10,000-fold (NR2 PvuII-HindIII-digested genomic DNA transfor-
                                                                                  NR3).  inhibition GS activity strains NR2 mants, single 6.7-kb fragment present digest                                                                                   NR4 reaches maximum ca. 55 , shallow slope NR3 DNA. faint line fragment arti-
                                                                                  wide range L-733,560 concentrations. profile resem-
fact film development present lanes                                                                                   bles curve pneumocandin inhibition CAI4R1 GS autoradiogram (data shown). results consis-
                                                                                  (Fig. 3B). contrast, GS activity strain NR3 entirely
tent genomic maps shown Fig. 4B C,                                                                                   resistant inhibition L-733,560 concentrations depict CaFKS1 locus 59 HindIII site alleles
                                                                                  10 mM. shape curve similar (strain NR3) (Fig. 4B), pAM600-mediated integrative dis-
                                                                                  titration curves shown inhibition enzyme activity ruption locus (Fig. 4C).
                                                                                  strains T25 T26 (Fig. 3B).
   inhibition GS activity strains NR2, NR3,                                                                                      evaluated susceptibility transformants
NR4 L-733,560 shown Fig. 5. Relative GS activity
                                                                                  parents antifungal antibiotics currently clinical wild-type strain CAI4, enzyme mutant
                                                                                  use (Table 2). Amphotericin B, itraconazole, fluconazole, nys-
                                                                                  tatin, ketoconazole, 5-fluorocytosine produced equivalent
                                                                                  zones inhibition strains. Strains T25 T26
                                                                                  Ura1 pJAM15 transformants strains NR2, NR3,
                                                                                  NR4 resistant known GS inhibitors,
                                                                                  including echinocandin B, pneumocandins, dihy-
                                                                                  dropapulacandin (data shown). specificity resis-
                                                                                  tance characteristic S. cerevisiae mutants selected 
                                                                                  sistance GS inhibitors, strains R560-1C (12)                                                                                   pbr1-1 (9).
                                                                                     step integrative transformation CaFKS1. sought
                                                                                  determine CaFKS1 essential gene. strat-
                                                                                  egy transform Ura2 strains bearing disrupted allele
                                                                                  CaFKS1 locus URA3-containing disruption plas-
                                                                                  mid targets CaFKS1 determine genotypes                                                                                   Ura1 transformants Southern blot analysis. CaFKS1
                                                                                  required viability, expected recover clones                                                                                   disruptions copies gene. disrupt                                                                                   allele, strain CAI4 transformed Ura1 plasmid
   FIG. 4. CaFKS1 locus Echr transformants mutant NR3.   Southern
                                                                                  pAM602, digested PvuII KpnI blot DNAs mutant strain NR3 (lane 1) pAM600 transformants       release Cafks1::hisG-URA3-hisG insert. Clones puri-
(strains T82 [lane 2], T83 [lane 3], T85 [lane 4]) digested PvuII    fied SC Ura2, genomic DNA analyzed Southern
HindIII probed 2.1-kb KpnI-BamHI CaFKS1 fragment                blots (Fig. 6). Transformant T6 disruption pJAD1. markers used described legend Fig. 2A. (B) Restriction
map homozygous Cafks1h locus strain NR3. symbols features                                                                                   Cafks1b allele (CaFKS1h/Cafks1b::hisG-URA3-hisG); diges- map described legend Fig. 2C. (C) Map pAM600 integration     tion genomic DNA strain T6 HindIII PvuII Cafks1h-3 strain NR3.                                                       yielded 6.7- 12-kb fragments. independent colonies
 2476       DOUGLAS ET AL.                                                                                                     ANTIMICROB. AGENTS CHEMOTHER.


                               TABLE 2. Susceptibilities CAI4-derived strains antifungal antibiotics clinical use

                             Amt                                                      Diam zone inhibition (mm) 
    Compound
                           (mg/spot)        CAI4         CAI4R1          T25         T26       T28      T32       NR2(Ura1)         NR3(Ura1)     NR4(Ura1)

Amphotericin B                 5             19            16            17          17         17       17            16              18            18
Itraconazole                  10             20            18            19          20         19       18            17              18            20
Fluconazole                    5             25            20            20          20         24       21            22              20            19
Nystatin                      10             24            20            20          21         20       20            18              24            23
Ketoconazole                   5             33            31            33          32         32       31            31              29            30
5-Fluorocytosine              10             16            14            16          16         15       14            14              16            16



 transferred plates containing 5-fluoroorotic acid                                 ment patterns, intact 8.5-kb CaFKS1b allele. (5FOA) uridine select loss URA3 gene (16).                              obtained similar results strain T6FOA1; 13 trans- Southern blot HindIII-PvuII-digested DNA                                  formants, pattern expected disruption Ura2 derivative (T6FOA1) revealed fragments (6.7                                  functional 6.7-kb CaFKS1h allele (Fig. 6 data shown).
9.3 kb), consistent loss URA3 gene retention                           Clones obtained spheroplast lithium acetate hisG insertion (CaFKS1/Cafks1b::hisG). CAI4 trans-                                transformation methods. able isolate nu-
formant T1 disruption CaFKS1h allele; genomic                                merous Cafks1::URA3/CaFKS1 transformants Cafks1::
DNA T1 yielded 8.5- 15-kb fragments digestion                               hisG/Cafks1::URA3 transformants, propose func- HindIII PvuII (Fig. 6). size insertion-                               tional CaFKS1 allele essential viability bearing allele consistent tandem integration                              growth transformation conditions.
cassettes (Cafks1h::hisG-URA3-hisG-URA3-hisG/CaFKS1b).                                  Growth rates, virulence, susceptibility L-733,560 structure confirmed additional Southern blot; di-                             vivo. reduced growth rate S. cerevisiae fks1 null mutants
gestion DNA strain T1 restriction                              poor growth weak virulence C. albicans Echr
enzymes cut 3.9-kb hisG-URA3-hisG cassette                               mutant M2 (27) confirm changes GS activity produced 3.9-kb fragment hybridized hisG probe                              detrimental cell. strain CAI4R1, shown (data shown). Ura2 derivative (T1FOA3) obtained fol-                                spontaneous Echr mutation significant effect lowing selection 5FOA analyzed (Fig. 6),                            growth vitro ability establish disseminated
fragment pattern (7.5- 8.5-kb HindIII-PvuII fragments)                                infection immunocompromised mice (27). Animals infected consistent retention single hisG cassette                                   Ura1 derivative heterozygous mutant required (Cafks1h::hisG/CaFKS1b).                                                                  ED99 L-733,560 approximately eightfold higher    second round targeted disruption Cafks1 locus                              animals infected strain CAI4(Ura1) (27). evaluated performed transforming plasmid pAM601, linearized                               consequences single-allele disruption CaFKS1
digestion SalI, strains T6FOA1 T1FOA3. Uri-                                 locus growth rate GS activity vitro dine prototrophs selected SC Ura2, genomic                                    LD50 ED99 L-733,560 vivo (Table 3). doubling
DNA analyzed Southern blots. 22 transfor-                                    times strains tested 80 110 min mants strain T1FOA3, 16 yielded pattern expected                               YPDAUd medium; dramatic effect Echr genotype Cafks1h::URA3/CaFKS1b (Fig. 6 data                                   mutations loss CaFKS1h CaFKS1b allele shown). remaining transformants complex frag-                                growth rate. specific activity GS strains
                                                                                          (Table 3) ranged 13 55 nmol mg21 h21;                                                                                           strain, GS activity varied replicate membrane prepara-
                                                                                          tions, differences twofold                                                                                           considered significant.  cells functional
                                                                                          CaFKS1b allele (T32) CaFKS1h allele (T25) sig-
                                                                                          nificantly impaired ability grow liquid culture                                                                                           express GS activity. animal model disseminated 
                                                                                          didiasis, LD50s ranged low 4,500 CFU/mouse
                                                                                          [strain NR2(Ura1)] high 330,000 CFU/mouse (strain
                                                                                          T6). Lethality relative functional diploid CAI4(Ura1)
                                                                                          slightly reduced  twofold) CaFKS1h
                                                                                          allele disrupted strain T1, disruption                                                                                           CaFKS1b allele strain T6 produced nearly 65-fold reduc-
                                                                                          tion LD50. heterozygous Echr mutants,
                                                                                          strain NR4(Ura1), mutant Cafks1b allele (Cafks1b-4/
   FIG. 6. Southern blot clones step integration CaFKS1                CaFKS1h) nearly 32-fold virulent strain CAI4
locus. DNA strain analyzed described legend Fig. 2.            (Ura1), LD50s strains wild-type
pAM602 transformation wild-type strain CAI4 (lane 1) produced transfor-                CaFKS1b alleles [CAI4R1(Ura1), Cafks1h-1/CaFKS1b; NR2
mants plasmid integration CaFKS1b allele (strain T6 [lane 2]) CaFKS1h allele (strain T1 [lane 10]). Clones selected 5FOA resistance
                                                                                          (Ura1), Cafks1h-2/CaFKS1b] essentially equivalent (strain T6FOA1 [lane 3] strain T1FOA3 [lane 11]) transformed                CAI4(Ura1). Strain NR3(Ura1), homozy-
pAM602, fragment profiles seven Ura1 transformants strain                  gous Cafks1h-3 allele, twofold virulent
T6FOA1 (T54 T59 [lanes 4 9, respectively]) transformants            wild-type diploid. Finally, CAI4R1-derived trans-
strain T1FOA3 (T3 T8 [lanes 12 17, respectively]) shown. positions markers  described legend Fig. 2, addition                                                                                           formants T25 T26 (Cafks1h-1/Cafks1b::URA3), 3.2-kb standard pJAD1DXH digested BamHI SalI) indicated                 strains T28 T32 (Cafks1h-1::URA3/CaFKS1b),  kilobases).                                                                           roughly 3- 10-fold virulent strain CAI4(Ura1).
 VOL. 41, 1997                                                                                               FKS1 GENE C. ALBICANS                2477


       TABLE 3. Analysis mutant strains growth GS activity vitro virulence pneumocandin susceptibility vivo
                                                                                    vitro                                    vivo

     Strain                                Genotype                       Doubling time                          14-day LD50              ED99 (mg/kg)
                                                                                               GS sp acta
                                                                             (min)                            (104 CFU/mouse)       L-733,560      AMBc
          1
CAI4(Ura )           CaFKS1h/CaFKS1b (pJAM15)                                  90                 31               0.51                0.06         0.05
T1                   Cafks1h::hisG-URA3-hisG-URA3-hisG/CaFKS1b                NDb                 ND               0.63                ND           ND
T6                   CaFKS1h/Cafks1b::hisG-URA3-hisG                          ND                  ND              33                   ND           ND
CAI4R1(Ura1)         Cafks1h-1/CaFKS1b (pJAM15)                                93                 55               0.47                0.25         0.03
T25                  Cafks1h-1/Cafks1b::URA3                                   85                 24               1.7                .6.0          0.14
T26                  Cafks1h-1/Cafks1b::URA3                                   90                 22               5.1                .6.0          0.05
T28                  Cafks1h-1::URA3/CaFKS1b                                  110                 13               2.8                 0.11         0.04
T32                  Cafks1h-1::URA3/CaFKS1b                                  100                 35               3.7                 0.03         0.02
NR2(Ura1)            Cafks1h-2/CaFKS1b (pJAM15)                               ND                  52               0.45                0.74         0.12
NR3(Ura1)            Cafks1h-3/Cafks1h-3 (pJAM15)                             ND                  53               1.1                .6.0          0.05
NR4(Ura1)            CaFKS1h/Cafks1b-4 (pJAM15)                                80                 19              16                   0.75         0.07
    Expressed nanomoles product hour21 milligram protein21.
 b
   ND, determined.
 c
   AMB, amphotericin B.



   evaluated susceptibilities strains treat-            CAI4 considerable homology FKS1. amino acid
ment L-733,560 mouse model. Animals infected                sequence predicted fragment 689 residues long, suspension strain 0.5 1 times 14-day              ca. 75  identity Fksp family proteins (Fks1p,
LD50 treated L-733,560 amphotericin B according                Fks2p, FksAp). identity proteins regimen outlined Materials Methods. ED99s                higher (88 ) comparison limited region L-733,560 (Table 3) used categorize strains              protein large, predicted cytoplasmic domain. distinct classes: strains T28, T32, CAI4(Ura1)              fragment CaFKS1 sufficient analysis, susceptible antibiotic; strains CAI4R1(Ura1),             entire open reading frame. remains seen NR2(Ura1), NR4(Ura1) susceptible, requiring 4                domains CaFks1p significant identity equivalent 13 times L-733,560 99  efficacy; strains T25,              regions proteins  nidulans S. cerevisiae.
T26, NR3(Ura1) significantly eliminated                  Preliminary data cloning sequencing FKS ho-
infected mice, highest dose L-733,560 tested.            molog C. neoformans suggests gene product Echr mutations did confer cross-resistance ampho-               remarkably conserved (23). Unlike genes FKS fam-
tericin B; ED99s strains, including T25, T26,              ily, genes encoding proteins involved chitin biosynthesis
NR3(Ura1) mutants, range 0.02 0.14 mg                (CHS genes) significantly divergent different fungal kg.  independent mutations conferred                genera (7), isozymes C. albicans (CaChs1p, vitro pneumocandin resistance liquid broth microdilu-              CaChs2p, CaChs3p) significantly different tion assay GS assay caused increase ED99s              (7, 19, 38, 44, 45). L-733,560 treatment disseminated candidiasis                  Integration URA3-based disruption plasmid pAM600
imal model.                                                                Cafks1 locus spontaneous C. albicans Echr
                                                                           mutants yielded mixture Echs Echr transformants.
                            DISCUSSION                                     Loss resistance phenotype Echs transformants    Numerous studies identified echinocandins GS                correlated disruption Cafks1h allele strains
inhibitors potential use novel antifungal drugs            CAI4R1 NR2 disruption Cafks1b allele treat human mycoses (31). development potent                strain NR4. results strain CAI4R1 confirm previous
inhibitors GS growing repertoire genetic                 study based spheroplast fusions genetically marked
molecular methods C. albicans, tools study              Echs strains (27), Echr phenotype role essential enzyme cell wall synthesis. Work            semidominant. diploid strain CAI4R1 nonpathogen S. cerevisiae shown GS                   (Cafks1h-1/CaFKS1b) consistently susceptible vitro
subunit Fks1p likely target echinocandin inhibition.             L-733,560 strains lacking functional Echs allele [T25 S. cerevisiae etg1-1 strain contains semidominant muta-              T26 (Cafks1h-1/Cafks1b::URA3)], difference small
tion leads echinocandin-resistant cells              (Fig. 3). recovered resistant sensitive
sistant GS activity. Recent studies C. albicans strain            pAM600 transformants CAI4R1, NR2, NR4, CAI4 identified rare spontaneous Echr mutants                Cafks1h-1, Cafks1h-3, Cafks1b-4 mutations 
amenable genetic analysis evaluated viru-                sidered dominant. addition, alleles expressed
lence. mutants phenotypes similar               growth conditions used study, muta- S. cerevisiae etg1-1 mutant, suspected mutant           tion CaFKS1h allele CaFKS1b allele 
Echr allele isolates homolog FKS1.             mits Echr/Echs heterozygotes grow medium supple- provided evidence pathogen C. albicans              mented L-733,560 sufficient kill Echs/Echs cells.
genetic segment specifying Fks1p homolog rare                 Strain NR3 unique echinocandin-resistant
mutations dominant alleles gene (CaFKS1).               mutants isolated.  allele detected inability isolate homozygous null mutants CaFKS1                 Southern blots NR3 genomic DNA digested HindIII
suggests essential survival C. albicans.                 PvuII, size consistent    CaFKS1 gene fragment cloned C. albicans                     CaFKS1h allele. Second, pAM600 transformants strain NR3
 2478     DOUGLAS ET AL.                                                                                       ANTIMICROB. AGENTS CHEMOTHER.

 uniformly Echr; recovered Echs derivatives           mutations, spontaneous induced 75 clones evaluated. fragment pattern observed          transformation, responsible differences virulence.
Southern blots transformants suggested            unable predict liquid broth microdilution
strains contained intact disrupted copy          assays GS IC50s strains resistant vivo
CaFKS1h allele (Fig. 4). rule possi-          treatment pneumocandin. Strain CAI4R1(Ura1) 
bility dominant Echr mutation locus,         sembles strains T25 T26 susceptibility vitro likely strain NR3 resistant alleles CaFKS1.           L-733,560 (Fig. 3A), vivo susceptibilities selective pressure imposed L-733,560, original            equivalent; infections strains T25 T26 required mutant allele duplicated gene conversion.          24-fold L-733,560 99  effective treatment mutation CaFKS1 locus recessive         infections strain CAI4R1(Ura1) (Table 3). Likewise, dominant. mutation recessive, support         IC50s L-733,560 GS activities strains NR2, NR3, idea types mutations FKS genes confer          NR4 (40,000, 30,000, 40 nM, respectively [Table 2])
resistance glucan synthase inhibitors laboratory, e.,     predict strains NR2(Ura1) NR3(Ura1) recessive weakly dominant mutations, S.           equally resistant vivo strain NR4(Ura1) cerevisiae etg1-4 (15) pbr1-1 (9) mutations, dom-      significantly susceptible.  infected animals,
inant mutations typified Cafks1h-1 mutation.                   strain NR3(Ura1) resistant L-733,560 (ED99
   Southern blots revealed fortuitous restriction frag-         . 6.0), ED99s strains NR2(Ura1) NR4(Ura1)
ment length polymorphism CaFKS1 locus              equivalent (0.74 0.75, respectively), values strumental distinguishing alleles demonstrating       eightfold lower strain NR3(Ura1). qual- disruption allele overtly deleterious       itative measure enzyme resistance, shape GS
der laboratory growth conditions, second forced integra-        titration curves L-733,560 inhibition, shown Fig. 3B tion yielded transformants plasmid integrated           5, represents best prediction pneumocandin susceptibil- preexisting disrupted allele. results suggest     ity vivo. Echr/Echs heterozygous mutants inter-
loss copies CaFKS1 gene lethal            mediate resistance vivo, GS inhibition curves sug-
event sufficiently disabling viable transformants       gest intermediate resistance, shallow slope detected. observation consistent inabil-      maximum 55  inhibition. know extent ity detect homolog CaFKS1 stringent conditions,         GS inhibition sufficient clear cell infected
like FKS2 gene S. cerevisiae rescue cells            animal, use GS IC50s defined lacking functional FKS1 gene.  nidulans (25),        warranted predict phenotypes vivo. addition,
FKS homolog detected restriction mapping hybrid-           variables vitro GS assay concentration ization analysis. 0.4-kb C. albicans gene fragment 47          crude membrane protein incubation temperature homology S. cerevisiae FKS2 gene identified             significant effect absolute IC50, evidenced random sequence analysis C. albicans genome (42),          results GS strain CAI4 shown Fig. 3B 5. role gene (CaFKS2) understood.                        Echr mutants characterized paper    disruption strategy used employed oth-          isolated high cell densities agar plates containing ers identify essential genes C. albicans, including HSP90,      pneumocandin L-733,560. strains represent member heat shock protein 90 family molecular             useful tool genetic characterization, relevance chaperones (46), KRE6, gene required b-1-6 glucan           potential clinical pneumocandin resistance unclear. Echr
synthesis (39). KRE6, important non-        organisms recovered C. albicans target-organ
essential genes C. albicans cell wall synthesis structure     model infection pneumocandin MK0991  identified. CHS2 (19) CHS3 (44) genes play          L-743,872) given neutropenic mice intraperitoneal role chitin synthesis; evidence CHS3 plays      administration (1, 43). outcome current future use
important role virulence animal models infection (8).      echinocandins pneumocandins humans provide gene (CHS1) identified, role remains           relevant information potential clinical resistance
unclear (38, 45). Mutants C. albicans PHR1 gene            new class antifungal antibiotics.
unable conduct apical growth yeast hyphal
growth form alkaline pH. Phr1 protein produced                          alkaline pHs shows strong identity Gas1p
                                                                      
glycosylphosphatidylinositol-anchored cell wall protein S.
cerevisiae. interesting GAS1 essential gene 
S. cerevisiae, loss GAS1 combined disruption      KRE6 PKC1 synthetically lethal (40).
   Virulence vivo susceptibility treatment L-                                    
733,560 assessed strains mouse model         
disseminated candidiasis. strain tested           
                                                                         
able establish lethal infection, LD50s equiv-      
alent, ranging 0.45 3 104 33 3 104 CFU/g kidney,              growth rate GS specific activity predictive   relative virulence. Reduced virulence does        associated disruption mutation specific allele.        wild-type CaFKS1b allele preserved               
strains low LD50s [CAI4(Ura1), T1, CAI4R1(Ura1),           NR2(Ura1)], strain lacks CaFKS1b allele                
tirely [NR3(Ura1)] transformants disrupted             
Cafks1b::URA3 allele (strains T25 T26) showed sig-          
nificant virulence mouse model (Table 3). possible          